Lipoprotein(a) and Vascular Redox State in Patients With Advanced Coronary Atherosclerosis
Arteriosclerosis, Thrombosis, and Vascular Biology · 2026-01 · 46 (1) · 232-247
DOI: 10.1161/atvbaha.125.322924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026-01. Verfasst von Murray D Polkinghorne und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.…. Hauptthemen laut MEDLINE: Lipoprotein(a), Coronary Artery Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Lp(a) (lipoprotein[a]) is associated with cardiovascular disease, but neither the causal nature nor the underlying mechanisms are fully documented. This study investigated whether Lp(a) triggers atherogenesis by dysregulating vascular redox–sensitive inflammatory state. METHODS: Plasma Lp(a) was measured in 1027 patients with advanced coronary artery disease undergoing cardiac surgery. These patients were genotyped, and a modified LPA genetic risk score (LPA GRS) determining Lp(a) levels was generated. RNA sequencing and vascular superoxide measurements were performed in internal mammary arteries, and the contribution of NOXs (NADPH oxidases) and uncoupled eNOS (endothelial nitric oxide synthase) was determined. The median follow-up was 5.07 years. RESULTS: Increased plasma Lp(a) ( P =0.03) and LPA GRS ( P =0.01) were associated with elevated arterial superoxide in the overall patient population, an effect that was driven by nondiabetics. This effect was primarily due to eNOS uncoupling via reduced vascular BH4 (tetrahydrobiopterin) bioavailability. There was no significant impact of Lp(a) variability on vascular NOX–derived superoxide ( P =0.13). RNA sequencing of arterial tissue revealed dysregulation of nitrosative and inflammatory signaling in high Lp(a) patients although there was no association with systemic biomarkers of inflammation (ie, hsCRP [high-sensitivity C-reactive protein]; P =0.82) or oxidative stress (ie, malondialdehyde; P =0.61). Finally, both LPA GRS (hazard ratio, 3.615 [95% CI, 1.044–12.515]; P =0.043) and high plasma Lp(a) (hazard ratio, 3.286 [95% CI, 1.003–10.767]; P =0.049) were associated with elevated risk for cardiac mortality. This association was vascular superoxide-dependent, implying that redox-sensitive inflammatory signaling may be a link between Lp(a) and cardiovascular risk. All the above associations were independent of plasma ApoB (apolipoprotein-B). CONCLUSIONS: This study demonstrates for the first time that a genetically determined increase in plasma Lp(a) results in dysregulated vascular redox/nitrosative signaling in patients with atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine (M.D.P., I.B., J.C., C.X., E.W., I.A., D.F., P.P., E.d.A., C.P.K., K.M.C., C.A.), University of Oxford, United Kingdom.
- Department of Metabolism, Digestion, and Reproduction, Imperial College London, United Kingdom (M.D.P.).
- Department of Excellence of Pharmacological and Biomolecular Sciences, University of Milan, Italy (A.B., G.D.N.).
- John Radcliffe Hospital, Oxford University Hospitals, United Kingdom (G.K, R.S., V.S., A.K., N.W., P.S.).
- Centre for Cardiovascular Sciences, The University of Edinburgh, United Kingdom (T.G.).
- Division of Cardiovascular Medicine, Acute Multidisciplinary Imaging and Interventional Centre (C.A.), University of Oxford, United Kingdom.
ORCID-Profile: Murray D Polkinghorne, Ileana Badi, Andrea Baragetti, Jagat Chauhan, Elizabeth Wahome, Ioannis Akoumianakis, Edmarcia de Araujo, George Krasopoulos, Rana Sayeed, Nicholas Walcot, Tomasz Guzik, Keith M Channon, Giuseppe D Norata, Charalambos Antoniades
Zitieren
APA
Polkinghorne, M. D., Badi, I., Baragetti, A., Chauhan, J., Xie, C., Wahome, E., Akoumianakis, I., Foran, D., Patel, P., de Araujo, E., Kotanidis, C. P., Krasopoulos, G., Sayeed, R., Srivastava, V., Kourliouros, A., Walcot, N., Sastry, P., Guzik, T., Channon, K. M., …, & Antoniades, C. (2026). Lipoprotein(a) and Vascular Redox State in Patients With Advanced Coronary Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 46(1), 232-247. https://doi.org/10.1161/atvbaha.125.322924
Vancouver
Polkinghorne MD, Badi I, Baragetti A, Chauhan J, Xie C, Wahome E, et al. Lipoprotein(a) and Vascular Redox State in Patients With Advanced Coronary Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026;46(1):232-247. doi:10.1161/atvbaha.125.322924
BibTeX
@article{Polkinghorne2026,
author = {Polkinghorne, Murray D and Badi, Ileana and Baragetti, Andrea and Chauhan, Jagat and Xie, Cheng and Wahome, Elizabeth and Akoumianakis, Ioannis and Foran, Daniel and Patel, Parijat and de Araujo, Edmarcia and Kotanidis, Christos P and Krasopoulos, George and Sayeed, Rana and Srivastava, Vivek and Kourliouros, Antonios and Walcot, Nicholas and Sastry, Priya and Guzik, Tomasz and Channon, Keith M and Norata, Giuseppe D and Antoniades, Charalambos},
title = {Lipoprotein(a) and Vascular Redox State in Patients With Advanced Coronary Atherosclerosis},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2026},
volume = {46},
number = {1},
pages = {232--247},
doi = {10.1161/atvbaha.125.322924}
}
EUVIMED